Middle East & Africa Autoinjectors Market Overview

The Middle East & Africa Autoinjectors Market was valued at USD 519.25 Million in 2025 and is projected to reach USD 1,690.95 Million by 2035, growing at a CAGR of 12.53%. It is the smallest of the five regions in the Global Autoinjectors Market report by revenue but the one with the longest runway: the diagnosis-gap conversion story that drives emerging-market demand applies here across the widest spread of income levels, from the Gulf's centralised, government-funded procurement to donor- and WHO-supported access in lower-income African markets.

Saudi Arabia is the region's most important regulatory market: the Saudi Food and Drug Authority (SFDA) has established specific guidance for combination-product classification and registration that recognises integrated prefilled drug-delivery systems, and in December 2025 it granted approval for the EMPAVELI Injector based on Enable Injections enFuse on-body technology. Elsewhere, the WHO prequalification track for GLP-1 and insulin products is the practical access mechanism for the lower-income markets inside the region. This report quantifies MEA across twelve segmentation axes and 27 segment tables, with dedicated analysis for Saudi Arabia, the United Arab Emirates, Other GCC countries, Israel, South Africa and the Rest of Middle East & Africa.

Middle East & Africa Autoinjectors Market by Country

• Rest of Middle East & Africa — USD 145.23 Million in 2025 to USD 465.98 Million by 2035 (12.36% CAGR); the region's largest single line, reflecting highly distributed demand across lower-income markets where WHO prequalification and donor-funded procurement are the practical access channels and the diagnosis-gap runway is the longest in the study.
• Saudi Arabia — USD 117.76 Million to USD 409.96 Million (13.29% CAGR); the largest country market and the fastest-growing. Centralised, government-led procurement means formulary and tender decisions move national volume in single steps — the regional analogue of the single-buyer dynamics analysed for government preparedness segments elsewhere in the report.
• United Arab Emirates — USD 71.34 Million to USD 238.09 Million (12.81% CAGR); the region's commercial and logistics hub, with early adoption of premium presentations and a distribution role extending beyond domestic demand.
• South Africa — USD 66.67 Million to USD 208.04 Million (12.05% CAGR); the continent's most developed pharmaceutical market and natural entry point, where growth tracks private-insurance coverage of biologics and public-sector access runs through WHO prequalification.
• Other GCC Countries — USD 60.02 Million to USD 194.84 Million (12.50% CAGR); centralised procurement at smaller scale, with growth tracking government health-investment programmes.
• Israel — USD 58.21 Million to USD 174.04 Million (11.57% CAGR); significant on the supply side — Teva, whose SIMLANDI and SELARSDI biosimilar autoinjector presentations are cited throughout the report, anchors a domestic generics and biosimilar industry for which device presentation is a core competitive variable.

What Shapes the MEA Market

Single-buyer procurement. In Saudi Arabia and the wider GCC, one tender decision can move national volume, which rewards suppliers with SFDA-compliant combination-product dossiers and reliable global capacity — the multi-continent footprints of SHL Medical, Ypsomed, Owen Mumford and Gerresheimer. The report's investment-scenario chapter treats government health programmes as the region's demand floor.

Untreated demand with the longest runway. The IDF Diabetes Atlas projects diabetes to reach 852.5 million adults by 2050, with Middle East and Africa among the fastest-growing prevalence regions, and the WHO Essential Medicines List now includes GLP-1 receptor agonists. As screening widens, that pool converts into injectable demand; therapeutic peptides and proteins (insulin, GLP-1) reach USD 344.79 Million by 2035 at 12.84% CAGR, faster than the regional market.

Biosimilars and affordable presentations. Teva's Israel-based biosimilar business, Celltrion, Samsung Bioepis, Fresenius Kabi and the Indian biosimilar majors profiled in the report supply the affordable biologic presentations that private insurers in South Africa and the Gulf are increasingly covering. Low-cost, drug-agnostic architectures such as Owen Mumford Autoject 2 matter more here than in Western markets.

Middle East & Africa Segment Insights

Monoclonal antibodies and fusion proteins reach USD 1,048.18 Million by 2035, about 62% of regional revenue, concentrated in the Gulf and South Africa where biologic coverage is established. Reusable systems (13.62% CAGR) and integrated connectivity (13.82%) grow faster than the regional market, driven by the UAE's early adoption of premium presentations and by cost-per-dose economics in tender-driven markets. Every segment is quantified for each of the six countries and sub-regions.

Market Drivers and Restraints in MEA

• Driver — government health investment. Gulf health programmes and centralised procurement fund biologic and GLP-1 access at national scale.
• Driver — SFDA combination-product framework. Clear classification and registration guidance lowers the qualification barrier for integrated prefilled devices; the SFDA's December 2025 approval of the enFuse-based EMPAVELI Injector shows the pathway working for large-volume on-body systems.
• Driver — WHO prequalification and donor procurement. The WHO prequalification channel opens tender-driven access for GLP-1 and insulin products across lower-income markets in the Rest of MEA grouping.
• Driver — regional supply base. Teva in Israel and the biosimilar exporters give the region a device-presentation supply chain of its own.
• Restraint — income dispersion and the availability discount. Listed prices and accessible prices diverge widely across the region; the report's emerging-market price-source section and methodology notes address this directly.
• Restraint — regulatory fragmentation. SFDA, the UAE MOHAP, Israel's Ministry of Health and South Africa's regulator each require local registration, multiplying qualification cost for a single presentation.
• Restraint — no local device manufacturing. Dependence on imported autoinjectors exposes the region to global capacity bottlenecks and to tariff-driven shifts in where platform specialists place capacity.

Competitive Landscape

Multinational pharma platform users — Novo Nordisk, Eli Lilly, Sanofi, AbbVie, Pfizer, AstraZeneca, Johnson & Johnson and UCB — lead branded revenue in the Gulf and South Africa, while Teva, Celltrion, Samsung Bioepis, Fresenius Kabi, Viatris, Lupin, Sun Pharmaceutical, Zydus and Biocon Biologics supply biosimilar and generic presentations. Devices come from SHL Medical, Ypsomed, Owen Mumford / embecta, Gerresheimer, Haselmeier, Nemera, Elcam (Israel) and Kindeva, with Enable Injections now SFDA-approved for on-body delivery; BD, West Pharmaceutical Services, SCHOTT Pharma, Nipro and Terumo anchor primary containers. The report profiles 151 companies across 15 chapters with company details, financials, product summary and recent developments.

Report Scope — Middle East & Africa

Key Questions Answered

• How large is the Middle East & Africa autoinjectors market and how fast will Saudi Arabia, the UAE, Other GCC, Israel, South Africa and the Rest of MEA each grow to 2035?
• How do SFDA combination-product rules and centralised Gulf procurement decide which device platforms win national tenders?
• Which biosimilar and GLP-1 presentations are entering the region, and through which channels — private insurance, government programmes or WHO prequalification?
• How wide is the gap between listed and accessible prices across the region, and how does it shape architecture and container-size choices?
• Which global device makers, biosimilar companies and primary-container suppliers are best positioned as Gulf health investment and African biologic coverage expand?

This regional report is drawn from the Global Autoinjectors Market report. Related coverage: North America, Europe, Asia-Pacific and Latin America autoinjectors market reports.